COVALENT ENZYME INHIBITION IN DRUG DISCOVERY AND DEVELOPMENT
Author:
- 6 December 2013
- book chapter
- Published by Wiley
- p. 81-129
Abstract
No abstract availableKeywords
This publication has 142 references indexed in Scilit:
- Reversible targeting of noncatalytic cysteines with chemically tuned electrophilesNature Chemical Biology, 2012
- Discovery of Potent and Selective Covalent Inhibitors of JNKChemistry & Biology, 2012
- In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native KinasesChemistry & Biology, 2011
- Redox cycling compounds generate H2O2 in HTS buffers containing strong reducing reagents—real hits or promiscuous artifacts?Current Opinion in Chemical Biology, 2011
- Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH InhibitorACS Medicinal Chemistry Letters, 2010
- Structure of a microsporidian methionine aminopeptidase type 2 complexed with fumagillin and TNP-470Molecular and Biochemical Parasitology, 2009
- Insight into the Mechanism of Inactivation of Ribonucleotide Reductase by Gemcitabine 5′-Diphosphate in the Presence or Absence of ReductantBiochemistry, 2009
- Synthesis and biological evaluation of p38α kinase-targeting dialkynylimidazolesBioorganic & Medicinal Chemistry Letters, 2009
- A Chemical and Genetic Approach to the Mode of Action of FumagillinChemistry & Biology, 2006
- Irreversible Inhibitors of Serine, Cysteine, and Threonine ProteasesChemical Reviews, 2002